Analysing a Biotechnology Company for its Innovation, Strategy and Technological Value
At i3 Consult we have been
successful in ensuring that a biotechnology client of ours retained a
significant portion of funds upon initiating their highly successful IPO. Our
client was a university based incubator company preparing for its IPO. In order
to do this, they needed a comprehensive evaluation of the protein biomarker
marketplace, including sales trends, competitive activity, client needs analysis
and analogous case studies of competitors. i3 Consult provided a final
valuation of investment funding, business angels and contingency VC funding.
This begs the question, how was this possible? Below is outlined our approach
to the project.
Our Approach
Focus groups/structured
teleconference meetings consisting of 5 to 10 team members each from a
cross-section of the Biotech company’s value chain were conducted to brainstorm
on the critical success factors that will procure a greater market share. As a
further refinement strategy, surveys of closed research instrument design
tested attitudes and perceptions of the client's current service offerings and
clearly defined future ones to a selected pool of potential big pharma
investors and licensing partners. The objective here was to confirm strategies
for synchronizing the Biotech player’s value chain with the R&D pipeline
needs of these investors. Full-scale value chain (Figure 1) and cost reduction
analyses were conducted to clearly identify the organisational and operational
transformations necessary for maximizing the profit margin. A full SWOT audit
of the Biotech’s R&D, operational, technological and digital systems was
conducted and reported for the client in a new business model road map.
(Source: A.T. Kearney analysis)
Figure 1: Biotech Value Chain Analysis
Comments
Post a Comment